| |
For researchers unaffiliated with an academic library, finding scientific papers can be time-consuming and expensive—and organizing or sharing them can be even harder. Can a new tool address this gap? Learn more. 
|
|
Today's Big NewsDec 5, 2022 |
| By James Waldron With the acquisition of Neogene Therapeutics this week and with a CAR-T now in phase 1 courtesy of a Chinese partnership, AstraZeneca hopes to add the first volumes to a planned “library” of off-the-shelf cell therapies. |
|
|
|
By Nick Paul Taylor Amgen’s late run for the obesity market is gathering pace. In phase 1, recipients of the highest dose of the company’s would-be challenger to Novo Nordisk’s Wegovy maintained double-digit percentage weight loss 150 days after receiving the last of three shots. |
By Conor Hale Each year, we ask for your help in bringing to our attention the companies you believe are the fiercest in medtech. |
By Nick Paul Taylor The FDA has set out its reasons for putting Verve Therapeutics’ high cholesterol gene editing therapy on hold. Officials want additional data to allay concerns that patients could pass on the edited genes to their children before they lift the clinical hold. |
|
Conducting ADME DDI studies early on in the development process can be so much more than a simple box checking exercise to satisfy regulatory requirements... Read More >> 
|
|
By Max Bayer Dermata Therapeutics' rosacea ambitions are in the red after the company’s lead asset failed a phase 2 trial, placing additional pressure on the med as an acne treatment. |
By Helen Floersh Scientists used a common biomedical material to create a non-hormonal birth control that stops sperm in its tracks, with promising findings in sheep. |
By Kevin Dunleavy With bankruptcy looming for Clovis Oncology, the company has reported in a securities filing that it has defaulted on a loan by failing to make an interest payment. Clovis also revealed that it has decided—at the request of the FDA—to restrict the use of its cancer drug Rubraca to those whose tumors have BRCA mutations. |
By Fraiser Kansteiner Pfizer is throwing down $750 million to upgrade sterile injectables production at its facility in Kalamazoo, Michigan, where the company cranked out some of the earliest COVID-19 vaccines in the U.S. The project is expected to generate 300 new jobs. |
By Andrea Park Medtronic’s HeartWare Ventricular Assist Device may be off the market, but it’s still very much on the company’s mind. |
By Ben Adams New York healthcare marketing agency Havas Health & You is partnering with software company Evermed to deliver tailored video content for doctors. |
By Heather Landi Despite the market downturn and economic pressures, the majority of investors expect digital health dollars in 2023 to be roughly on par with 2020, bringing in an estimated $15 billion to $25 billion. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we discuss the current state of Biogen and recent investor reactions to the new hire. Plus we cover the week's news including: What Albert Bourla said that has him in hot water, a $3.5 million drug, and we tease a possible major acquisition. |
|
|---|
|
|
|
Thursday, December 15, 2022 | 11am ET / 8am PT Cell therapy products have amazing potential to treat a wide variety of diseases and vast numbers of patients globally. In this webinar we discuss what these key challenges are, how to approach these challenges and some opportunities available to better the process. Register now. 
|
|
Video Revolutionize your monoclonal antibody (mAb) manufacturing with expert insights. Sponsored by: Gibco |
Whitepaper Learn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
